Shane Adam Shapiro

Shane Adam Shapiro

Auto-generated profile, based on publicly available information

Shane Adam Shapiro

Department of Orthopedic Surgery, Mayo Clinic, Jacksonville, FL, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2018 in Cells
Verified
Journal Article
Open access
PDF file
SBSara Busatto
Sara Busatto
GVGeorge Vilanilam
George Vilanilam
TTTaylor Ticer
Taylor Ticer
WLWen-Lang Lin
Wen-Lang Lin
DDDennis W. Dickson
Dennis W. Dickson
JWJoy Wolfram
Joy Wolfram
Concentration of extracellular vesicles (EVs) from biological fluids in a scalable and reproducible manner represents a major challenge. This study reports the use of tangential flow filtration (TFF) for the highly efficient isolation of EVs from large volumes of samples. When compared to ultracentrifugation (UC), which is the most widely used method to concentrate EVs, TFF is a more efficient, scalable, and gentler method. Comparative assessment of TFF and UC of conditioned cell culture media revealed that the former concentrates EVs of comparable physicochemical characteristics, but with higher yield, less single macromolecules and aggregates (<15 nm in size), and improved batch-to-batch consistency in half the processing time (1 h). The TFF protocol was then successfully implemented on fluids derived from patient lipoaspirate. EVs from adipose tissue are of high clinical relevance, as they are expected to mirror the regenerative properties of the parent cells.

30 September 2016 in The American Journal of Sports Medicine
Verified
Journal Article
Closed access
SSShane A. Shapiro
Shane A. Shapiro
SKShari E. Kazmerchak
Shari E. Kazmerchak
MHMichael G. Heckman
Michael G. Heckman
AZAbba C. Zubair
Abba C. Zubair
MOMary I. O’COnnor
Mary I. O’COnnor
Bone marrow aspirate concentrate (BMAC) is increasingly used as a regenerative therapy for musculoskeletal pathological conditions despite limited evidence-based support. BMAC will prove feasible, safe, and efficacious for the treatment of pain due to mild to moderate degenerative joint disease of the knee. Randomized controlled trial; Level of evidence, 2. In this prospective, single-blind, placebo-controlled trial, 25 patients with bilateral knee pain from bilateral osteoarthritis were randomized to receive BMAC into one knee and saline placebo into the other. Fifty-two milliliters of bone marrow was aspirated from the iliac crests and concentrated in an automated centrifuge. The resulting BMAC was combined with platelet-poor plasma for an injection into the arthritic knee and was compared with a saline injection into the contralateral knee, thereby utilizing each patient as his or her own control. Safety outcomes, pain relief, and function as measured by Osteoarthritis Research Society International (OARSI) measures and the visual analog scale (VAS) score were tracked initially at 1 week, 3 months, and 6 months after the procedure. There were no serious adverse events from the BMAC procedure. OARSI Intermittent and Constant Osteoarthritis Pain and VAS pain scores in both knees decreased significantly from baseline at 1 week, 3 months, and 6 months (P ≤ .019 for all). Pain relief, although dramatic, did not differ significantly between treated knees (P > .09 for all). Early results show that BMAC is safe to use and is a reliable and viable cellular product. Study patients experienced a similar relief of pain in both BMAC- and saline-treated arthritic knees. Further study is required to determine the mechanisms of action, duration of efficacy, optimal frequency of treatments, and regenerative potential. ClinicalTrials.gov record 12-004459.

1 September 2019 in Ageing Research Reviews
Verified
Journal Article
Closed access
ASAnnie Suh
Annie Suh
APAnthony Pham
Anthony Pham
MCMikel Jean Cress
Mikel Jean Cress
TPThais Pincelli
Thais Pincelli
STSarvam P. TerKonda
Sarvam P. TerKonda
SSShane A. Shapiro
Shane A. Shapiro

30 August 2018 in CARTILAGE
Verified
Journal Article
Closed access
PDF file
SSShane A. Shapiro
Shane A. Shapiro
JAJennifer R. Arthurs
Jennifer R. Arthurs
MHMichael G. Heckman
Michael G. Heckman
JBJoseph M. Bestic
Joseph M. Bestic
SKShari E. Kazmerchak
Shari E. Kazmerchak
MOMary I. O’cOnnor
Mary I. O’cOnnor
Bone marrow aspiration and concentration (BMAC) is becoming a more common regenerative therapy for musculoskeletal pathology. In our current pilot study, we studied patients with mild-to-moderate bilateral knee osteoarthritis, compared pain at 12-month follow-up between BMAC-injected and saline-injected knees, and examined cartilage appearance measured by magnetic resonance imaging (MRI) T2 quantitative mapping. Twenty-five patients with mild-to-moderate bilateral osteoarthritic knee pain were randomized to receive BMAC into one knee and saline placebo into the other. Bone marrow was aspirated from the iliac crests, concentrated in an automated centrifuge, combined with platelet-poor plasma for knee injection, and compared with saline injection into the contralateral knee. Primary outcome measures were T2 MRI cartilage mapping at 6-month and Visual Analog Scale and Osteoarthritis Research Society International Intermittent and Constant Osteoarthritis Pain scores and radiographs at 12-month follow-up. Constant, intermittent, and overall knee pain remained significantly decreased from baseline at 12-month follow-up (all P ⩽ 0.01), with no apparent difference between BMAC- and saline-treated knees (all P ⩾ 0.54). A similar significant increase from baseline to 12-month follow-up regarding quality of life was observed for both BMAC- and saline-treated knees (all P ⩽ 0.04). T2 quantitative MRI mapping showed no significant changes as a result of treatment. BMAC is safe to perform and relieves pain from knee arthritis but showed no superiority to saline injection at 12-month follow-up. MRI cartilage sequences failed to show regenerative benefit with single BMAC injection. The mechanisms of action that led to pain relief remain unclear and warrant further studies.

1 November 2021 in Clinical Journal of Sport Medicine
Verified
Journal Article
Closed access
JFJonathan T. Do Finnoff
Jonathan T. Do Finnoff
TATariq M. Do Awan
Tariq M. Do Awan
JBJoanne Borg-Stein
Joanne Borg-Stein
KHKimberly G Harmon
Kimberly G Harmon
DHDaniel C Herman
Daniel C Herman
SSShane A. Shapiro
Shane A. Shapiro
Many sports medicine physicians are currently considering introducing regenerative medicine into their practice. Regenerative medicine and the subclassification of orthobiologics are a complicated topic and have produced widely varying opinions. Although there is concern by government regulators, clinicians, scientists, patient advocacy organizations, and the media regarding the use of regenerative medicine products, there is also excitement about the potential benefits with growing evidence that certain regenerative medicine products are safe and potentially efficacious in treating musculoskeletal conditions. Sports medicine physicians would benefit from decision-making guidance about whether to introduce orthobiologics into their practice and how to do it responsibly. The purpose of this position statement is to provide sports medicine physicians with information regarding regenerative medicine terminology, a brief review of basic science and clinical studies within the subclassification of orthobiologics, regulatory considerations, and best practices for introducing regenerative medicine into clinical practice. This information will help sports medicine physicians make informed and responsible decisions about the role of regenerative medicine and orthobiologics in their practice.

21 November 2022 in Extracellular Vesicle
Verified
Journal Article
Open access
SWSierra Walker
Sierra Walker
IDIrina Davidovich
Irina Davidovich
YYYubo Yang
Yubo Yang
ALAndrew Lai
Andrew Lai
Jenifer Pendiuk GonçalvesJenifer Pendiuk Gonçalves
Jenifer Pendiuk Gonçalves
JWJoy Wolfram
Joy Wolfram
Advancements in extracellular vesicle (EV) studies necessitate the development of optimized storage conditions to ensure preservation of physical and biochemical characteristics. In this study, the most common buffer for EV storage (phosphate-buffered saline/PBS) was compared to a cryoprotective 5% sucrose solution. The size distribution and concentration of EVs from two different sources changed to a greater extent after −80 °C storage in PBS compared to the sucrose solution. Additionally, molecular surface protrusions and transmembrane proteins were more prevalent in EVs stored in the sucrose solution compared to those stored in PBS. This study demonstrates, for the first time, that distinct ring-like molecular complexes and cristae-like folded membranous structures are visible upon EV degradation. Taken together, the size, concentration, molecular surface extensions, and transmembrane proteins of EVs varied substantially based on the buffer used for −80 °C storage, suggesting that biocompatible cryoprotectants, such as sucrose, should be considered for EV studies.